



## Latuda<sup>®</sup> (lurasidone) – Expanded indication

- On March 6, 2018, [Sunovion announced](#) the FDA approval of [Latuda \(lurasidone\)](#) for monotherapy treatment of pediatric patients (10 to 17 years) with major depressive episode associated with bipolar I disorder (bipolar depression).
  - Previously, Latuda was only approved for monotherapy treatment of adults with major depressive episode associated with bipolar I disorder.
  - Latuda is also indicated for the treatment of adult and adolescent patients (13 to 17 years) with schizophrenia and as adjunctive treatment with [lithium](#) or valproate [eg, [Depakote<sup>®</sup> \(divalproex sodium\)](#)] in adult patients with major depressive episode associated with bipolar I disorder.
- The efficacy of Latuda for the expanded indication was established in a placebo-controlled study of 343 pediatric patients with major depressive episode associated with bipolar I disorder. The primary endpoint was the change from baseline in Children’s Depression Rating Scale, Revised (CDRS-R) score at week 6.
  - Latuda was superior to placebo in reduction of CDRS-R score (placebo subtracted difference in CDRS-R score: -5.7; 95% CI: -8.4, -3.0).
- Latuda carries a boxed warning for increased mortality in elderly patients with dementia-related psychosis, and suicidal thoughts and behaviors.
- The most common adverse reactions (≥ 5% and at least twice the rate for placebo) with Latuda use for pediatric patients with bipolar depression were nausea, weight increase, and insomnia.
- The recommended starting dose of Latuda for monotherapy treatment of bipolar depression in pediatric and adult patients is 20 mg orally once daily. Initial dose titration is not required. The daily dose may be increased up to 120 mg for adults and 80 mg for children.
- Refer to the Latuda prescribing information for dosing recommendations for all other indications.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.